BOGZ1FL663067003Q: z=+3.26 extreme analogs: 1985, 1997, 2001 (worst S&P 12m -22%)
Today's read — 2026-07-22
most extreme macro
BOGZ1FL663067003Q at +3.26σ (above historical mean). Security broker/dealer margin accounts (Z.1 memo item).
freshest distress
SANGAMO THERAPEUTICS, INC — severe distress. Score 1.00. Filed 2026-07-20. Look at unsecured creditor recovery vs. bond price for trade.
next hard catalyst
PDUFA OTLK on 2026-07-29. Outlook Therapeutics, Inc.: PDUFA action date 2026-07-29 (8-.
smart-money consensus
MICROSOFT CORP — 1 managers buying vs 4 selling, net $-2.34B. Consensus 13F selling (Q1 2026).
What you're looking at
merger arbRisk-free return if the announced deal closes. Spread % = (offer − price) / price.
structural zHow extreme each macro variable is vs its 30-yr history. |z|≥3 is a sub-1% historical event.
13F consensusWhat the 14 tracked managers (Buffett, Klarman, Ackman, …) bought/sold last quarter.
catalyst calendarUpcoming binary events with hard dates: FDA approvals, Fed meetings, index rebals, Ph3 readouts.
Ch.11 distressFresh bankruptcy filings ranked by stage and recency. Severe = within 7d of petition + DIP.
HY ETF prem/discCredit-stress early warning. Discount to NAV = credit selling pressure.
stub pairsParent market cap minus value of holdings. Negative stub = the market values the parent's other business below zero (Paulson/Pellegrini archetype).
scanner health 7m ago scanner_health.py
PASS analysis rows=10.0s
PASS edgar.search rows=50.4s
PASS edgar.full_text rows=100.3s
PASS structural_scan rows=4318.0s
PASS merger_arb.discover rows=1261.4s
PASS merger_arb.scan_ex rows=30.5s
PASS stub_scanner rows=8421.6s
PASS regulatory rows=463.0s
PASS catalyst_calendar rows=1822.6s
PASS bankruptcy rows=56.6s
PASS thirteen_f rows=50.8s
structural z-scores 40s ago FRED — Pellegrini engine
| # | series | class | signed z | level | vs ATH/ATL | rank | as of | description |
|---|---|---|---|---|---|---|---|---|
| 1 | BOGZ1FL663067003Q | leverage | +3.26 | 622.20K | ● at ATH | top 0.0% | 2026-01-01 | Security broker/dealer margin accounts (Z.1 memo item) |
| 2 | MSACSR | leverage | +2.34 | 10.30 | -15.6% below ATH | top 2.7% | 2026-05-01 | Monthly supply of houses (months supply) |
| 3 | HOSMEDUSM052N | price_div | +2.23 | 440.60K | ● at ATH | top 0.0% | 2026-06-01 | Median sale price of new houses |
| 4 | NCBDBIQ027S | leverage | +2.10 | 8.98M | ● at ATH | top 0.0% | 2026-01-01 | Nonfinancial corporate debt to GDP ratio |
| 5 | TLAACBW027SBOG | leverage | +1.99 | 25.62K | ● at ATH | top 0.0% | 2026-07-08 | Total assets, all commercial banks |
| 6 | HDTGPDUSQ163N | leverage | -1.58 | 68.55 | +0.9% above ATL | bottom 1.2% | 2025-04-01 | Household debt to GDP, US (BIS) |
| 7 | NASDAQCOM | price_div | +1.57 | 25.84K | -4.6% below ATH | top 7% | 2026-07-21 | NASDAQ Composite — concentration narrative gauge |
| 8 | USSTHPI | price_div | +1.34 | 713.09 | ● at ATH | top 14% | 2026-01-01 | All-transactions House Price Index, US |
| 9 | SP500 | price_div | +1.21 | 7.51K | -1.3% below ATH | top 10% | 2026-07-21 | S&P 500 index level (nominal) |
| 10 | PSAVERT | credit_coll | +1.17 | 3.00 | -90.6% below ATH | bottom 9% | 2026-05-01 | Personal saving rate — low = credit-fueled spending |
| 11 | BAMLH0A3HYC | narrative | -1.11 | 9.77 | +41.6% above ATL | top 8% | 2026-07-20 | ICE BofA CCC & lower HY OAS — junk-of-junk complacency |
| 12 | BAMLH0A0HYM2 | narrative | +1.11 | 2.69 | -41.6% below ATH | bottom 8% | 2026-07-20 | ICE BofA US High Yield OAS — low = complacency |
merger arb spreads 21s ago EDGAR DEFM14A/S-4 + yfinance
no deals passed the sanity floor (15 deals found but offer_value could not be parsed from filings — EDGAR proxy/S-4 parsing may need updated patterns)
regulatory events 12s ago EDGAR 8-K + FTC RSS
| sev | src | date | tkr | class | headline |
|---|---|---|---|---|---|
| crit | FTC | 2026-07-14 | prohibition | FTC Secures Major Settlement with Caremark, Resolving Antitrust Case Against Second Drug M | |
| crit | FTC | 2026-07-13 | prohibition | FTC Secures $12 Million in Penalties for Pre-Merger Reporting Act Violations | |
| crit | FTC | 2026-07-02 | prohibition | FTC and DOJ Issue Fiscal Year 2025 Hart-Scott-Rodino Annual Report | |
| crit | FTC | 2026-06-30 | prohibition | FTC Secures Agreement with Havas to Restore Competition in the Digital Advertising Ecosyst | |
| crit | FTC | 2026-06-22 | prohibition | FTC Approves Final Consent Order in Pest-Control Noncompete Matter | |
| high | EDGAR-8K | 2026-07-21 | ISSC | statement_of_objections | INNOVATIVE SOLUTIONS & SUPPORT INC 8-K mentions 'statement of objections' |
| high | EDGAR-8K | 2026-07-20 | PSNL | second_request | Personalis, Inc. 8-K mentions 'second request' |
| high | EDGAR-8K | 2026-07-20 | TEM | second_request | Tempus AI, Inc. 8-K mentions 'second request' |
| high | EDGAR-8K | 2026-07-16 | ETSY | phase_ii_opened | ETSY INC 8-K mentions 'Phase 2 investigation' |
| high | EDGAR-8K | 2026-07-15 | CTAS | second_request | CINTAS CORP 8-K mentions 'second request' |
| high | EDGAR-8K | 2026-07-14 | DIOD | second_request | DIODES INC /DEL/ 8-K mentions 'second request' |
| high | EDGAR-8K | 2026-07-13 | VEEE | second_request | Twin Vee PowerCats, Co. 8-K mentions 'second request' |
| high | EDGAR-8K | 2026-07-07 | RES | second_request | RPC INC 8-K mentions 'second request' |
| high | EDGAR-8K | 2026-07-01 | VAL | second_request | Valaris Ltd 8-K mentions 'second request' |
| high | EDGAR-8K | 2026-07-01 | RIG | second_request | Transocean Ltd. 8-K mentions 'second request' |
| high | EDGAR-8K | 2026-07-01 | UNF | second_request | UNIFIRST CORP 8-K mentions 'second request' |
| high | EDGAR-8K | 2026-07-01 | FMC | second_request | FMC CORP 8-K mentions 'second request' |
| high | EDGAR-8K | 2026-06-30 | DEA | second_request | Easterly Government Properties, Inc. 8-K mentions 'second request' |
| high | EDGAR-8K | 2026-06-30 | PATK | second_request | PATRICK INDUSTRIES INC 8-K mentions 'second request' |
| high | EDGAR-8K | 2026-06-30 | LCII | second_request | LCI INDUSTRIES 8-K mentions 'second request' |
catalyst calendar 2s ago EDGAR 8-K PDUFA + FOMC + index rebal
| date | type | ticker | timing | description |
|---|---|---|---|---|
| 2026-07-29 | pdufa | OTLK | scheduled | Outlook Therapeutics, Inc.: PDUFA action date 2026-07-29 (8-K 2026-06-16) |
| 2026-08-05 | pdufa | MRNA | expected | Moderna, Inc.: PDUFA action date 2026-08-05 (8-K 2026-05-01) |
| 2026-08-17 | pdufa | PFE | expected | PFIZER INC: PDUFA action date 2026-08-17 (8-K 2026-05-05) |
| 2026-08-22 | pdufa | CAPR | expected | CAPRICOR THERAPEUTICS, INC.: PDUFA action date 2026-08-22 (8-K 2026-05-07) |
| 2026-08-25 | pdufa | ZYME | expected | Zymeworks Inc.: PDUFA action date 2026-08-25 (8-K 2026-05-07) |
| 2026-08-27 | pdufa | GILD | expected | GILEAD SCIENCES, INC.: PDUFA action date 2026-08-27 (8-K 2026-05-07) |
| 2026-09-18 | pdufa | NUVL | expected | Nuvalent, Inc.: PDUFA action date 2026-09-18 (8-K 2026-05-07) |
| 2026-09-27 | pdufa | PRAX | expected | Praxis Precision Medicines, Inc.: PDUFA action date 2026-09-27 (8-K 2026-06-29) |
| 2026-09-28 | pdufa | BFRI | expected | Biofrontera Inc.: PDUFA action date 2026-09-28 (8-K 2026-05-14) |
| 2026-07-29 | fomc | RATES | scheduled | FOMC policy decision / press conference |
| 2026-09-16 | fomc | RATES | scheduled | FOMC policy decision / press conference |
| 2026-08-28 | index_rebal | MSCI | expected | MSCI quarterly index review effective |
| 2026-09-18 | index_rebal | S&P 500 | expected | S&P quarterly rebalance effective |
| 2026-07-24 | trial_phase3 | Qlaris B | inferred | Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension (NCT NCT07354 |
| 2026-07-30 | trial_phase3 | Quoin Ph | inferred | Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome (NCT NCT0695 |
| 2026-07-30 | trial_phase3 | Innervat | inferred | Open-Label Study of 18F-mFBG for Imaging Neuroblastoma (NCT NCT04724369) |
| 2026-08-01 | trial_phase3 | Xenon Ph | inferred | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (N |
| 2026-08-01 | trial_phase3 | HALEON | inferred | Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Denti |
| 2026-09-01 | trial_phase3 | Agitated | inferred | Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Rig |
| 2026-09-01 | trial_phase3 | Incyte C | inferred | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-interm |
chapter 11 dockets 1s ago EDGAR 8-K full-text
| date | ticker | issuer | reason | score |
|---|---|---|---|---|
| 2026-07-20 | SGMOQ | SANGAMO THERAPEUTICS, INC | voluntary petition | severe |
| 2026-07-16 | NOTVQ | Inotiv, Inc. | debtor-in-possession | severe |
| 2026-07-15 | LIPO | LIPELLA PHARMACEUTICALS INC. | voluntary petition | severe |
| 2026-06-23 | SGMO | SANGAMO THERAPEUTICS, INC | voluntary petition | severe |
| 2026-06-23 | OPIRQ | OFFICE PROPERTIES INCOME TRUST | debtor-in-possession | severe |
stub pairs 2m ago parent/sub mcap diff
| parent | sub | parent mcap | stake value | stub value | z-score |
|---|---|---|---|---|---|
| SFTBY | ARM | $206.98B | $278.51B | $-71.52B | -2.20 |
| FWONA | FWONK | $22.58B | $24.54B | $-1.95B | +0.07 |
| LBRDK | CHTR | $4.31B | $4.09B | $222M | +1.68 |
| LBRDA | CHTR | $4.31B | $4.09B | $224M | +1.68 |
| IAC | MGM | $3.14B | $2.34B | $805M | -1.78 |
HY ETF prem/disc 1m ago yfinance — HYG JNK HYLB USHY
| ETF | price | NAV | prem/disc | z-score | status | as of |
|---|---|---|---|---|---|---|
| JNK | $95.90 | $95.93 | -0.027% | -0.98 | normal | 2026-07-22 09:22 |
| HYLB | $36.35 | $36.40 | -0.148% | -0.94 | normal | 2026-07-22 09:22 |
| HYG | $79.65 | $79.64 | +0.008% | -0.89 | normal | 2026-07-22 09:21 |
| USHY | $36.86 | $36.87 | -0.038% | -0.88 | normal | 2026-07-22 09:23 |
corporate pivots 2s ago EDGAR 8-K + press wires
no pivot candidates in last 60 days (this is normal — genuine pivots are rare)
distressed equity reversals stale EDGAR 8-K/13D/Form 4 + yfinance — ≥60% drawdown gated by event catalyst
| ticker | name | dd | DD score | tier | value | P/TBV | ROIC | FCF m | M | why | catalysts |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BNGO | Bionano Genomics, Inc. | 77% | 7.55 | — | — | — | — | — | — | not analyzed yet | ceo_change · ceo_resign · strategic_review |
| BRTX | BioRestorative Therapies, In | 82% | 7.25 | — | — | — | — | — | — | not analyzed yet | ceo_change · ceo_resign |
| FRMI | Fermi Inc. | 80% | 5.69 | — | — | — | — | — | — | not analyzed yet | ceo_change · ceo_resign · separation … |
| GNPX | Genprex, Inc. | 99% | 5.53 | — | — | — | — | — | — | not analyzed yet | strategic_review |
| CRMT | AMERICAS CARMART INC | 93% | 5.37 | — | — | — | — | — | — | not analyzed yet | strategic_review |
| ZSQR | Z Squared Inc. | 68% | 5.36 | — | — | — | — | — | — | not analyzed yet | ceo_change · ceo_resign |
| BNC | CEA Industries Inc. | 89% | 5.04 | — | — | — | — | — | — | not analyzed yet | ceo_change · ceo_resign |
| BNCWW | CEA Industries Inc. | 95% | 5.04 | — | — | — | — | — | — | not analyzed yet | ceo_change · ceo_resign |
| BNCWZ | CEA Industries Inc. | 81% | 5.04 | — | — | — | — | — | — | not analyzed yet | ceo_change · ceo_resign |
| CVKD | Cadrenal Therapeutics, Inc. | 85% | 5.01 | — | — | — | — | — | — | not analyzed yet | ceo_change · ceo_resign · separation … |
| ADTX | Aditxt, Inc. | 100% | 4.95 | — | — | — | — | — | — | not analyzed yet | ceo_change · ceo_resign · ioi … |
| ZONE | CleanCore Solutions, Inc. | 91% | 4.89 | — | — | — | — | — | — | not analyzed yet | ceo_change · separation · strategic_review |
| GPRO | GoPro, Inc. | 75% | 4.83 | — | — | — | — | — | — | not analyzed yet | strategic_review |
| WAST | WASTE ENERGY CORP. | 83% | 4.53 | — | — | — | — | — | — | not analyzed yet | ceo_change · ceo_resign |
| MTNB | Matinas BioPharma Holdings, | 88% | 4.32 | — | — | — | — | — | — | not analyzed yet | ceo_resign · ioi · separation … |
| NOTE | FiscalNote Holdings, Inc. | 99% | 3.98 | — | — | — | — | — | — | not analyzed yet | ceo_change · strategic_review |
| XCUR | EXICURE, INC. | 77% | 3.96 | — | — | — | — | — | — | not analyzed yet | ceo_change · ceo_resign · strategic_review |
| TOVX | Theriva Biologics, Inc. | 73% | 3.75 | — | — | — | — | — | — | not analyzed yet | strategic_review |
value-screen cache: 0/68 tickers have fundamental analysis cached. Daily render workflow pre-warms these. Locally:
python value_screen.py scan --max-tickers 80smart money — cross-manager 13F changes Q1 2026 · 16w · next ~Aug 14 EDGAR 13F-HR — Q1 2026 vs Q4 2025 (period: 2026-03-31 vs 2025-12-31)
| type | manager | period | issuer | new val | old val | delta $ | Δ shares % |
|---|---|---|---|---|---|---|---|
| INCREASED | BERKSHIRE | Q1 2026 | CHEVRON CORPORATION | $12.05B | $295M | $11.76B | +2906% |
| INCREASED | BERKSHIRE | Q1 2026 | ALPHABET INC | $11.87B | $5.59B | $6.29B | +131% |
| DROPPED | GATES | Q1 2026 | MICROSOFT CORP | $0 | $3.72B | $-3.72B | -100% |
| DROPPED | BERKSHIRE | Q1 2026 | VISA INC | $0 | $2.91B | $-2.91B | -100% |
| NEW | BERKSHIRE | Q1 2026 | DELTA AIR LINES INC | $2.65B | $0 | $2.65B | +100% |
| DROPPED | BERKSHIRE | Q1 2026 | MASTERCARD INCORPORATED | $0 | $2.28B | $-2.28B | -100% |
| NEW | PERSHING_SQUARE | Q1 2026 | MICROSOFT CORP | $2.09B | $0 | $2.09B | +100% |
| DECREASED | PERSHING_SQUARE | Q1 2026 | ALPHABET INC | $89M | $1.93B | $-1.84B | -95% |
| DECREASED | BERKSHIRE | Q1 2026 | CONSTELLATION BRANDS INC | $95M | $1.79B | $-1.70B | -95% |
| DECREASED | GATES | Q1 2026 | BERKSHIRE HATHAWAY INC DEL | $8.17B | $9.75B | $-1.59B | -12% |
| DROPPED | BERKSHIRE | Q1 2026 | DOMINOS PIZZA INC | $0 | $1.40B | $-1.40B | -100% |
| NEW | BERKSHIRE | Q1 2026 | ALPHABET INC | $1.03B | $0 | $1.03B | +100% |
| DROPPED | BERKSHIRE | Q1 2026 | UNITEDHEALTH GROUP INC | $0 | $1.02B | $-1.02B | -100% |
| NEW | SCION | Q3 2025 | PALANTIR TECHNOLOGIES INC | $912M | $0 | $912M | +100% |
| INCREASED | BERKSHIRE | Q1 2026 | NEW YORK TIMES CO MTN BE | $1.15B | $254M | $897M | +275% |
| DROPPED | PERSHING_SQUARE | Q1 2026 | HILTON WORLDWIDE HLDGS INC | $0 | $870M | $-870M | -100% |
| DROPPED | BERKSHIRE | Q1 2026 | POOL CORP | $0 | $702M | $-702M | -100% |
| DROPPED | BERKSHIRE | Q1 2026 | AON PLC | $0 | $618M | $-618M | -100% |
| DROPPED | THIRD_POINT | Q1 2026 | PG&E CORP | $0 | $551M | $-551M | -100% |
| DROPPED | BERKSHIRE | Q1 2026 | AMAZON COM INC | $0 | $525M | $-525M | -100% |
13F consensus — cross-manager overlap Q1 2026 · 16w · next ~Aug 14 Q1 2026 vs Q4 2025 — grouped by issuer, buyers vs sellers, net Δ$
| issuer | buyers | sellers | net Δ$ | managers |
|---|---|---|---|---|
| MICROSOFT CORP | 1 | 4 | $-2.34B | GATES, PERSHING_SQUARE, THIRD_POINT |
| UNITEDHEALTH GROUP INC | 0 | 3 | $-1.17B | BERKSHIRE, SCION, APPALOOSA |
| ALIBABA GROUP HLDG LTD | 0 | 3 | $-468M | APPALOOSA, THIRD_POINT, SCION |
| JD.COM INC | 0 | 3 | $-122M | APPALOOSA, SCION, OAKTREE |
| ALPHABET INC | 4 | 2 | $5.32B | BERKSHIRE, PERSHING_SQUARE, BERKSHIRE |
| PG&E CORP | 1 | 3 | $-563M | THIRD_POINT, THIRD_POINT, THIRD_POINT |
| AMAZON COM INC | 3 | 2 | $-57M | BERKSHIRE, APPALOOSA, PERSHING_SQUARE |